3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
163
Endometrial Neoplasms
13
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
5
Recurrence
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Intraductal, Noninfiltrating
4
Triple Negative Breast Neoplasms
3
Breast Diseases
3
Breast Cancer Metastatic
3
Prostatic Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Lobular
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Polycystic Ovary Syndrome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Neoplastic Cells, Circulating
1
Neoadjuvant Operable Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphangioleiomyomatosis
1
Interventions
Fulvestrant
3
Alpelisib
3
parsaclisib
2
Paclitaxel
2
Irinotecan
2
Cetuximab
2
Carboplatin
2
tanezumab
1
talazoparib
1
sotorasib
1
serabelisib
1
sapanisertib
1
ruxolitinib
1
olaparib
1
niraparib
1
liposomal doxorubicin
1
inavolisib
1
dapagliflozin
1
ceralasertib
1
binimetinib
1
berzosertib
1
avelumab
1
Vemurafenib
1
Topotecan
1
Taxes
1
SF 1126
1
Oxaliplatin
1
Lomustine
1
Leuprolide
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hereditary Sensory and Autonomic Neuropathies
×
Letrozole
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts